Peptides Blocking CXCR4 Receptor for HIV-1 Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CXCR4 antagonists, such as AMD3100, face challenges in long-term treatments due to toxic side effects, and there is a need for effective antagonists that can block X4 tropic HIV-1 infection and regulate CXCR4 activity without adverse effects.
Innovation Solution
Development of specific peptides with defined amino acid sequences that effectively block X4 tropic HIV-1 infection by targeting the CXCR4 receptor, inhibiting bacterial pathogens, and modulating stem cell mobilization and T cell migration, while being less toxic and more potent than existing compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AMD3100 is used as a CXCR4 antagonist for long term treatments, then stem cell mobilization is achieved, but toxic side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure from small molecule compounds (AMD3100) to peptide structures with specific amino acid sequences. This structural parameter change results in compounds that maintain stem cell mobilization efficacy while reducing toxic side effects, as the peptide structure allows for selective CXCR4 antagonism with improved safety profile
Solution Approach 2:
The invention uses composite materials by designing peptides composed of specific amino acid building blocks (X, X0, X1, X2, X3, X4, X5, V, X6, X7, X8, X9 with defined substitutions) that work together to achieve both efficacy and safety. The composite peptide structure combines hydrophobic, hydrophilic, and structurally diverse residues to optimize binding to CXCR4 while minimizing off-target toxicity
2Reliability
If CXCR4 antagonists are developed to block X4 tropic HIV-1 infection, then antiviral activity is improved, but selectivity and reduced off-target effects are challenging
Solution Approach 1:
The patent applies local quality by designing specific regions within the peptide sequence to interact with particular domains of the CXCR4 receptor. The defined amino acid positions (X1-R, H or K; X2-Y, F, S or W; X4 and X5=K or C) create localized interaction zones that provide high selectivity for CXCR4 over other receptors, enabling potent antiviral activity against X4-tropic HIV-1 with minimal off-target effects
Data Source
AI summary
A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 μM.